PUREOTCMiscellaneous Chemical ProductsUS GAAP · USD

Pure Bioscience, Inc.

PURE Bioscience, Inc. develops and commercializes antimicrobial products based on patented stabilized ionic silver technology. Its core offerings use Silver Dihydrogen Citrate (SDC) in liquid formulations for sanitation, disinfection, and food-safety applications, and the company also supplies SDC-based ingredients for personal care uses.

Liikevaihto2,2milj. USD
+12,2 %v/v
Liikevoitto (EBIT)−2,3milj. USD
+28,8 %v/v
EBIT-marginaali−103,2%
+59,4 %-yks.v/v
Nettotulos−2,4milj. USD
+28,4 %v/v
Vapaa kassavirta−2,0milj. USD
+21,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−5,0−2,50,02,55,07,5milj. USD2020: 6,9 milj. USD2020: EBIT 0,00 milj. USD20202021: 3,9 milj. USD2021: EBIT −2,3 milj. USD20212022: 1,9 milj. USD2022: EBIT −3,7 milj. USD20222023: 1,9 milj. USD2023: EBIT −3,9 milj. USD20232024: 2,0 milj. USD2024: EBIT −3,2 milj. USD20242025: 2,2 milj. USD2025: EBIT −2,3 milj. USD20252,2−2,3
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Food safety sanitizers and disinfectants60 %

EPA/FDA/Health Canada-registered SDC products used on food-contact surfaces and in processing environments.

Direct food-contact processing aids20 %

SDC formulations used in food processing applications where direct contact is permitted.

Raw material ingredients10 %

SDC supplied as an ingredient for third-party personal care and related formulations.

Contract manufacturing10 %

Manufacture and sale of SDC-based products for end use or as manufacturing inputs.

Tuotteet

Raportoitu · osuus liikevaihdosta
90,6%9,2%FY2025100 %
  • PURE Hard Surface90,6 %
  • Sil Verion9,2 %
  • Royalty0,2 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

PURE sells to food-industry end users that need antimicrobial control across production, handling, and transport. Its products are also sold through distributors, which broadens access to smaller accounts and regional markets. The customer base includes restaurant chains, food processors, food manufacturers, and transportation companies, plus third parties that buy SDC as an ingredient or formulation input.

Restaurant chains

Buy food-contact surface sanitizer/disinfectant for hygiene and compliance.

Food processors

Use PURE Control and related SDC products in processing environments.

Food manufacturers

Purchase antimicrobial products to support sanitation and food safety.

Food transportation companies

Use sanitizing products for surfaces and handling equipment in transit.

Distributors

Buy and resell SDC products to extend market reach and local coverage.

Personal care formulators

Source SDC as a raw ingredient for third-party product formulations.

Strategia

PURE’s strategy centers on commercializing its SDC platform in food safety, expanding through distributors, and adding new products and applications. It also seeks third-party partnerships for approvals outside the U.S. and aims to protect its intellectual property while broadening the technology platform into additional revenue streams.

Grow the distribution networkLyhyt aikaväli

Distributors extend reach, reduce logistics burden, and speed market access.

Pursue approvals and partnerships outside the U.S.Keskipitkä aikaväli

International approvals can open new markets without building a full direct-sales footprint.

Develop new proprietary products and applicationsKeskipitkä aikaväli

New formulations can broaden the platform beyond current food-safety uses.

Protect intellectual propertyPitkä aikaväli

Patent protection supports differentiation and helps defend the SDC platform.

Maantiede

PURE is a U.S.-based company and its registered products are cleared for use in the United States, with additional registration in Canada. The business is built around domestic commercialization and distributor-led reach, while also pursuing third-party approvals for markets outside the U.S. Geography matters because regulatory approvals, local distributor coverage, and food-safety standards shape where the products can be sold.

Riskit

PURE faces commercialization risk because its products must gain broader acceptance in a competitive food-safety market where customers are price-sensitive and incumbents are larger and better resourced. The company also depends on regulatory approvals, distributor execution, and external financing, so delays in sales adoption or capital access could materially affect operations.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing and going-concern risk1Limited market acceptance of SDC products2Intense competition from larger food-safety companies3Regulatory approval delays4Intellectual property protection risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea

    Operations depend on external capital until operating cash generation improves.

    Kohdistuu: Liquidity and dilution

  2. Limited market acceptance of SDC productsVaikutus: KorkeaTodennäköisyys: Korkea

    Customers may not adopt the products broadly despite efficacy benefits.

    Kohdistuu: Food safety market

  3. Intense competition from larger food-safety companiesVaikutus: KorkeaTodennäköisyys: Korkea

    Rivals have broader product lines, stronger brands, and more resources.

    Kohdistuu: Food safety and sanitation products

  4. Regulatory approval delaysVaikutus: KeskitasoTodennäköisyys: Korkea

    Sales depend on EPA, FDA, Health Canada, and other approvals.

    Kohdistuu: Product registration and market entry

  5. Intellectual property protection riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The platform depends on patents and proprietary formulations for differentiation.

    Kohdistuu: Patent claims and enforcement

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Sales are recognized when performance obligations are satisfied, so shipment and delivery timing matter.

Vaikutus: Quarterly revenue comparability

Deferred revenue

Customer prepayments are held until the related product or service is delivered.

Vaikutus: Balance sheet liabilities and future revenue conversion

Inventory and manufacturing cost allocation

Direct and indirect production costs are capitalized into inventory before expensing through COGS.

Vaikutus: Gross margin and inventory valuation

R&D and product registration costs

Testing, personnel, and registration expenses are expensed as incurred.

Vaikutus: Operating expense volatility

Going-concern assessment

Liquidity assumptions influence whether financial statements require special disclosure and classification judgments.

Vaikutus: Financial statement presentation and risk disclosure

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Pure Bioscience, Inc. (OTC) – Miscellaneous Chemical Products | Analyysi – Clarifo